Wetenschappelijke publicaties

Meer details over citaties op Google Scholar Public Profile


  1. Out HJ, Derksen RHWM, Christiaens GCML. Systemische lupus erythematosus en zwangerschap. Amstelveen: Nationale Vereniging LE-patienten, 1988. ISBN: 90-71141-33-0.
  2. Derksen RHWM, Out HJ, Christiaens GCML. Lupus erythematosus disseminatus en zwangerschap. Ned Tijdschr Geneeskd 1989; 133: 1025-1029.
  3. Out HJ, Derksen RHWM, Christiaens GCML. Systemic lupus erythematosus and pregnancy. Obstet Gynecol Surv 1989; 44: 585-591.
  4. Out HJ, De Groot PhG, Hasselaar P, Van Vliet M, Derksen RHWM. Fluctuations of anti-cardiolipin antibody levels in patients with systemic lupus erythematosus: a prospective study. Ann Rheum Dis 1989; 48: 1023-1028.
  5. Asherson RA, Khamashta MA, Ordi-Ros J, Derksen RHWM, Machin SJ, Barquinero LJ, Out HJ, Harris EN, Vilardell-Torres M, Hughes GRV. The “primary” antiphospholipid syndrome: Major clinical and serological features. Medicine (Baltimore) 1989; 68: 366-374.
  6. Out HJ, Kater L, Derksen RHWM. Antiphospholipid antibodies: risk factors or only markers for thrombosis, fetal loss and thrombocytopenia? (editorial) Neth J Med 1990; 36: 177-181.
  7. Out HJ, De Groot PhG, Van Vliet M, Nieuwenhuis HK, De Gast GC, Derksen RHWM. Antibodies to platelets in patients with anti-phospholipid antibodies. Blood 1991; 77: 2655-2659.
  8. Out HJ, Bruinse HW, Christiaens GCML, Van Vliet M, Meilof JT, De Groot PhG, Smeenk RJT, Derksen RHWM. The prevalence of anti-phospholipid antibodies in patients with fetal loss. Ann Rheum Dis 1991; 50: 553-557.
  9. Out HJ, Kooijman CD, Bruinse HW, Derksen RHWM. Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies. Eur J Obstet Gynaecol Reprod Biol 1991; 41: 179-186.
  10. Out HJ, Bruinse HW, Derksen RHWM. Antiphospholipid antibodies and pregnancy loss. Hum Reprod 1991; 6: 889-897.
  11. Out HJ, Van Vliet M, De Groot PhG, Derksen RHWM. A prospective study on fluctuations of lupus anticoagulant activity and anticardiolipin antibody titre in patients with systemic lupus erythematosus. Ann Rheum Dis 1992; 51: 353-357.
  12. Out HJ, Bruinse HW, Christiaens GCML, Van Vliet M, De Groot PhG, Nieuwenhuis HK, Derksen RHWM. A prospective, controlled multicenter study on the obstetric risks of pregnant women with anti-phospholipid antibodies. Am J Obstet Gynecol 1992; 167: 26-32.
  13. Derksen RHWM, Out HJ, Blokzijl L, De Groot PhG. Lupus anticoagulant in pregnancy (letter). Clin Exp Rheumatol 1992; 10: 323-324.
  14. Out HJ, Derksen RHWM, De Groot PhG. Lupus anticoagulant activity and anticardiolipin antibody titre in patients with systemic lupus erythematosus. Ann Rheum Dis 1992; 51: 1021-1022 (reply to letter).
  15. Out HJ. Antifosfolipiden antistoffen: Diagnostiek en klinische betekenis. Analyse 1992; 47: 246-248.
  16. Out HJ, Mannaerts BMJL, Driessen SGAJ, Coelingh Bennink HJT. A prospective, randomized, assessor-blind, multicentre study comparing recombinant and urinary follicle-stimulating hormone (Puregon vs Metrodin) in in-vitro fertilization. Hum Reprod 1995; 10: 2534-2540.
  17. Hedon B, Out HJ, Hugues JN, Camier B, Cohen J, Lopes P, Zorn JR, Van der Heijden B, Coelingh Bennink HJT. Efficacy and safety of recombinant FSH (Puregon) in infertile women pituitary-suppressed with triptorelin undergoing in-vitro fertilisation: A prospective, randomised, assessor-blind, multicentre trial. Hum Reprod 1995; 10; 3102-3106.
  18. Hedon B, Out HJ, Hugues JN, Camier B, Cohen J, Lopes P, Zorn JR, Van der Heijden B, Coelingh Bennink HJT. Effacité et sécurité d’emploi d’une FSH recombinée (Puregon) après blocage hypophysaire par la tritoreline chez des femmes infertiles soumises à une FIV – etude clinique multicentrique, prospective, randomisée, lue en aveugle. Jobgyn 1996; 4: 35-42
  19. Out HJ, Schnabel PG, Rombout F, Geurts TBP, Bosschaert MAR, Coelingh Bennink HJT. A bioequivalence study of two urinary follicle stimulating hormone preparations: Follegon and Metrodin. Hum Reprod 1996; 11: 61-63.
  20. Mannaerts BMJL, Rombout F, Out HJ, Coelingh Bennink HJT. Clinical profiling of recombinant follicle stimulating hormone (rFSH; Puregon): relationship between serum FSH and efficacy. Hum Reprod Update 1996: 2: 153-161.
  21. Out HJ, Mannaerts BMJL, Driessen SGAJ, Coelingh Bennink HJT. Recombinant follicle stimulating hormone (rFSH; Puregon) in assisted reproduction: More oocytes, more pregnancies. Results from five comparative studies. Hum Reprod Update 1996: 2: 162-171.
  22. Geurts TBP, Peters MJH, van Bruggen JGC, de Boer WHJ, Out HJ. Puregon – (Org 32489) – recombinant human follicle-stimulating hormone. Drugs of Today 1996; 32: 239-258.
  23. Out HJ. Future preparations. From 75 IU freeze-dried cakes of HMG to 50 IU lyospheres of recombinant follicle-stimulating hormone. Orgyn 1996; 3: 29-31.
  24. Out HJ, Coelingh Bennink HJT. Puregon in assisted reproduction. More oocytes, more pregnancies. Puregon Orgyn special issue 1996; 7-13
  25. Out HJ, Olijve W, Coelingh Bennink HJT. The coming of wonders [Letter]. Fertil Steril 1997; 67: 411-413.
  26. Out HJ, Reimitz PE, Coelingh Bennink HJT. A prospective, randomized, study to assess the tolerance and efficacy of intramuscular and subcutaneous administration of recombinant follicle-stimulating hormone (Puregon). Fertil Steril 1997; 67: 278-283.
  27. Out HJ, Driessen SGAJ, Mannaerts BMJL, Coelingh Bennink HJT. Recombinant follicle-stimulating hormone (follitropin beta, Puregon) yields higher pregnancy rates in in vitro fertilization than urinary gonadotropins. Fertil Steril 1997; 68: 138-142
  28. Jones HW Jr, Out HJ, Hoomans EHM, Driessen SGAJ, Coelingh Bennink HJT. Cryopreservation: The practicalities of evaluation. Hum Reprod 1997; 12: 1522-1524.
  29. Out HJ, Donderwinkel PFJ, Fauser BCJM, Coelingh Bennink HJT. The use of a high-dose combined oral contraceptive preparation for suppression of endogenous gonadotrophins in a bioequivalence study of two urinary gonadotrophin preparations. Middle East Fertility Society Journal 1997; 2: 120-127.
  30. Duijkers IJM, Klipping C, Mulders TMT, Out HJ, Coelingh Bennink HJT, Vemer HM. Pharmacodynamics and pharmacokinetics after repeated subcutaneous administration of three gonadotropin preparations. Hum Reprod 1997; 12: 2379-2384.
  31. Coelingh Bennink HJT, Fauser BCJM, Out HJ, for the European Puregon Collaborative Anovulation Study Group. Recombinant FSH (Puregon) is more efficient than urinary FSH (Metrodin) in clomiphene-resistant normogonadotropic chronic anovulatory women: A prospective, multicenter, assessor-blind, randomised, clinical trial. Fertil Steril 1998; 69: 19-25.
  32. Devroey P, Tournaye H, Van Steirteghem A, Hendrix P, Out HJ. The use of a 100 IU starting dose of recombinant FSH (Puregon) in in-vitro fertilization. Hum Reprod 1998; 13: 565-566.
  33. Out HJ, Coelingh Bennink HJT. Clomiphene citrate in the twenty-first century: An anachronism? Assisted Reproduction Reviews 1998; 8: 94-101.
  34. Out HJ, Coelingh Bennink HJT. Drawing conclusions from imperfect data – Isn’t that what science does all the time? [Reply-to-letter] Fertil Steril 1998; 70: 385.
  35. Out HJ, Coelingh Bennink HJT. Clomiphene citrate or gonadotrophins for induction of ovulation? Hum Reprod 1998; 13: 2358-2361.
  36. Jansen CAM, Van Os HC, Out HJ, Coelingh Bennink HJT. A prospective randomised clinical trial comparing recombinant follicle-stimulating hormone (Puregon) and human menopausal gonadotrophins (Humegon) in non-downregulated in-vitro fertilization patients. Hum Reprod 1998; 13: 2995-2999.
  37. Out HJ, Olijve W, Coelingh Bennink HJT. Recombinant FSH (Puregon): biotechnology and clinical results. Cell 1998; 30: 150-155,
  38. Out HJ. New stimulation regimens with recombinant FSH (Puregon) in in-vitro fertilization. Eur J Obstet Gynecol Reprod Biol 1999; 85: 21-22.
  39. Devroey P, Tournaye H, Van Steirteghem A, Hendrix P, Out HJ. Ovarian stimulation [Reply-to-letter]. Hum Reprod 1999; 14: 865.
  40. Out HJ, Mannaerts BMJL, Driessen SGAJ, Coelingh Bennink HJT. A pregnancy and children follow-up study of three randomised clinical trials with recombinant follicle stimulating hormone (Puregon) in in-vitro fertilization. Middle East Fertility Society Journal 1999; 4: 28-34.
  41. Out HJ, Lindenberg S, Mikkelsen AL, Eldar-Geva T, Healy DL, Leader A, Rodriguez-Escudero FJ, Garcia-Velasco JA, Pellicer A. A prospective, randomised, double-blind clinical trial to study the efficacy and efficiency of a fixed dose of recombinant follicle stimulating hormone (Puregon®) in women undergoing controlled ovarian hyperstimulation. Hum Reprod 1999; 14: 622-627.
  42. Out HJ. Anovulatory infertility and the role of recombinant follicle-stimulating hormone (Recagon). J Indian Med Assoc 1999; 97: 37-40.
  43. Kahn JA, Sunde A, von During V, Out HJ. A prospective randomized comparative cohort study of either recombinant FSH (Puregon) or urinary FSH (Metrodin) in in vitro fertilization treatment. Middle East Fertility Society Journal 1999; 4: 206-214.
  44. Out HJ, Coelingh Bennink HJT, De Laat WNGM. What are the clinical benefits of recombinant gonadotrophins? The development of recombinant follicle stimulating hormone (Puregon®): A scientific business. Hum Reprod 1999; 14: 2189-2190.
  45. Out HJ, Braat DDM, Lintsen BME, Gurgan T, Bukulmez O, Gokmen O, Keles G, Caballero P, Gonzalez JM, Fabregues F, Balasch J, Roulier, R. Increasing the daily dose of recombinant follicle-stimulating hormone (Puregon®) does not compensate for the age-related decline in retrievable oocytes after controlled ovarian hyperstimulation. Hum Reprod 2000; 15: 29-35.
  46. Out HJ, Hoomans E, de Laat WNGM. Meta-analysis on rFSH versus uFSH. [Letter-to-the-editor]. Hum Reprod 2001; 16: 593-595.
  47. Out HJ, David I, Ron-El R, Friedler S, Shalev E, Geslevich J, Dor J, Shulman A, Ben-Rafael Z, Fisch B, Dirnfeld M. A randomised double-blind clinical trial using fixed daily doses of 100 or 200 IU of recombinant FSH in ICSI cycles. Hum Reprod 2001; 16: 1104-1109
  48. The Latin-American Puregon IVF study group. A double-blind clinical trial comparing a fixed daily dose of 150 and 250 IU of recombinant follicle stimulating hormone in women undergoing in vitro fertilisation. Fertil Steril 2001; 76: 950-956 (writer of the protocol and initial co-ordinator of the trial; writer of the manuscript, corresponding author).
  49. Sykes D, Out HJ, Palmer SJ, van Loon J. The cost-effectiveness of in vitro fertilisation in the United Kingdom: A comparison of three gonadotrophin treatments. Hum Reprod 2001; 16: 2557-2562.
  50. Out HJ, Mannaerts BMJL. The gonadotrophin releasing hormone antagonist ganirelix: History and introductory data. Human Fertility 2002; 5: G5-G12.
  51. The oral contraceptive and hemostasis study group. The effects of seven monophasic oral contraceptive regimens on hemostatic variables: Conclusions from a large randomised multicenter study. Contraception 2003; 67: 173-185 (corresponding author only).
  52. Out HJ, Rutherford A, Fleming R, Tay CCK, Trew G, Ledger W, Cahill D. A randomised double-blind multi-centre clinical trial comparing a starting dose of 150 and 200 IU of recombinant FSH in women treated with the GnRH-antagonist ganirelix for assisted reproduction. Hum Reprod 2004; 19: 90-95.
  53. Out HJ. Recombinant follicle-stimulating hormone: Gold standard or not? Reproductive Biomedicine Online 2005; 11: 536-539.
  54. Out HJ. Ten years of Puregon. Fertility Matters Special 2006
  55. Out HJ, Thomas LE. Optimizing the gonadotrophin dose regimen. Int Surg 2006; 91: S15-S24.
  56. Out HJ, Broekmans AW. Wetenschappelijke business. Kritiek op geneesmiddelenonderzoek is ongegrond. Medisch Contact 2007; 62: 1024-7.
  57. Out HJ, Broekmans AW. Letter-to-the -editor on editorial Vandenbroucke and Van der Meer: “Onafhankelijkheid van medici en van medisch onderzoek”. Ned Tijdschr Geneeskd 2009; 153: A749.
  58. Out HJ. Gastredactioneel: “Slecht voor Uw gezondheid?” C2W Medicines 2009; 3: 6.
  59. Out HJ. The Randomized Controlled Clinical Trial. EJHP Practice 2010; 16 (5): 52-53.
  60. Van Lent M, Out HJ. Industry tie may be benchmark of quality [Letter-to-the-editor]. Br Med J 2011; 343: 493.
  61. Out HJ, Lisman J. “Kwaliteit van geneesmiddeladvertenties in NTvG en PW” [Letter-to-the-editor] Ned Tijdsch Geneeskd 2012; 156: A3999
  62. Van Lent, Out HJ. Effect of funding source on publication bias is not so clear cut [Letter-to-the-editor]. Br Med J 2013; 347: f7582.
  63. Van Lent M, Overbeke J, Out HJ. Recommendations for a uniform assessment of publication bias related to funding source. BMC Medical Research Methodology 2013; 13: 120
  64. Out HJ. Data from industry funded trials are reliable enough to be published [Letter-to-the-editor]. Br Med J 2014; 348: g1298.
  65. van Lent M, Overbeke J, Out HJ. Role of Editorial and Peer Review Processes in Publication Bias: Analysis of Drug Trials Submitted to Eight Medical Journals. PLOS ONE 2014; 9(8): e104846
  66. Van Lent M, Rongen GA, Out HJ. Shortcomings of protocols of drug trials in relation to sponsorship as identified by Research Ethics Committees: analysis of comments raised during ethical review. BMC Medical Ethics 2014, 15:83
  67. Van Lent M, IntHout J, Out HJ. Differences between information in registries and articles did not influence publication acceptance J Clin Epidemiol 2015; 68: 1059-1067
  68. Van Lent M, IntHout J, Out HJ. Peer Review Comments on Drug Trials Submitted to Medical Journals Differ Depending on Sponsorship, Results, and Acceptance: A Retrospective Cohort Study. BMJ Open 2015;5:e007961

Hoofdstukken in boeken en overige

  1. Out HJ. Co-ordinator Excerpts on Human Reproduction, number 1, May 1996. The development of Puregon, a recombinant FSH. Oxford University Press.
  2. Out HJ. Co-editor: Recombinant FSH (Puregon). Preclinical and clinical experience. Parthenon Publishing Group, 1996, Carnforth, UK. ISBN 1-85070-746-4.
  3. Geurts TBJ, Peters MJH, van Bruggen JGC, de Boer W, Out HJ. Gonadotrophins into the next century: the research and development of Puregon. In: Practical Guide to Reproductive Medicine. Edited by Rainsbury PA, Viniker DA. Parthenon Publishing Group, 1997, Carnforth, UK. ISBN: 1-85070-727-8.
  4. Mannaerts BMJL, Rombout F, Out HJ, Coelingh Bennink HJT. Clinical profiling of recombinant follicle-stimulating hormone (rFSH; Puregon): Relationship between serum FSH and efficacy. In: Coutifaris C, Mastroianni L, eds. New Horizons in Reproductive Medicine; the Proceedings of the 9th World Congress in Human Reproduction, Philadelphia, 1996. New York: Parthenon, 1997: 169-79 (The International Congress, Symposium and Seminar Series; Volume 12).
  5. Out HJ. Co-ordinator Excerpts on Human Reproduction, number 1, October 1997. Further studies on Puregon, a recombinant FSH. Oxford University Press.
  6. Out HJ. Puregon in patients with chronic anovulation. In: Infertility and Assisted Reproductive Technology. From Research to Therapy. Edited by Ambrosini A, Melis GB, Dalla Pria S, Dessole S.. Monduzzi Editore, Bologna, 1997.
  7. Out HJ, Olijve W, Mannaerts BMJL, Coelingh Bennink, HJT. FSH recombinante (Puregon) en Reproduccion Asistida. In: Esterilidad, edited by Comparato MR. Segunda edicion, Argentina.
  8. Out HJ. Follitropin beta (Puregon). In: Biopharmaceuticals, an Industrial Perspective. Edited by Gary Walsh, Brendan Murphy. Kluwer Academic Publishers, Dordrecht, 1999. ISBN 0-7923-5746-9.
  9. Out HJ. Co-ordinator monograph Surveillance 1998 (Fertility & Sterility 1999, volume 71, supplement 2) 1999), edited by Howard Jones Jr and Jean Cohen.
  10. Out HJ, Hoomans EHM. New stimulation regimens with recombinant follicle stimulating hormone. Proceedings Third World Congress of Ovulation Induction. Editor: Marco Filicori. CIC Edizioni Internazionali, Rome, 2001.
  11. Out HJ. Should treatment with clomiphene continue? Proceedings 2nd World Congress on Controversies in Obstetrics, Gynecology and Infertility. Monduzzi Editore, Bologna, 2001.
  12. Out HJ. Side effects of drugs commonly used for induction of ovulation. In: Sathanandan SM and Jacobs HS. Handbook for ovulation induction. Imperial College Press, London, 2002.
  13. Out HJ. Synthesis and pharmacology of recombinant follicle-stimulating hormone, pp59-67. In: Revelli A, Tur-Kaspa I, Holte JG, Massobrio M, editors: Biotechnology of Human Reproduction. Parthenon, London, 2003.
  14. Out HJ. Co-ordinator monograph Surveillance 2004 (Fertility & Sterility 2004, volume 81; Supplement 4), edited by Howard Jones Jr and Jean Cohen.
  15. Out HJ. “….., diens woord men spreekt? De financieringsbron als kwaliteitskenmerk van klinisch geneesmiddelenonderzoek.” Inaugural oration. Radboudumc, 2011
  16. Out HJ, Van Meurs P, Van Olden R, 2013, editors, “Handboek Farmaceutische Geneeskunde”, Bohn Stafleu Van Loghem, Houten, The Netherlands
  17. Van Lent M, Out HJ. Integriteit en kwaliteit van klinisch geneesmiddelenonderzoek, 2013 In: 
“Handboek Farmaceutische Geneeskunde”, Bohn Stafleu van Loghum, Houten, The Netherlands.
  18. Out HJ. De pil en trombose. In: Waar maken artsen zich druk om? Selectie van blogs op Artsennet 2013, Reed Amsterdam.
  19. Out HJ. Vage vergoedingsdiscussies vertragen toegang tot nieuwe medicijnen. In: Snelle toelating of bewezen effectief en veilig? Twintig columnisten geven hun visie op het versneld toelaten van nieuwe geneesmiddelen. Jubileumuitgave Instituut voor Verantwoord Medicijngebruik, November 2015.
  20. Out HJ. “Leve het Geneesmiddel! Over de verdiensten van de farmaceutische industrie.” Prometheus, September 2016